The Supposedly Undruggable RAS Overcome: A New Era with Daraxonrasib in Pancreatic Cancer

RASolute 302 Study: Survival Doubled with Daraxonrasib

Study design

RASolute 302 is a global, open-label, randomized phase 3 study. It enrolled patients with metastatic pancreatic ductal adenocarcinoma who had previously received one line of chemotherapy for metastatic disease. Patients were randomized to daraxonrasib 300 mg orally once daily or investigator-selected standard cytotoxic chemotherapy.

Main efficacy results

The study met all primary and key secondary endpoints. In the ITT population, median overall survival was, with daraxonrasib, 13,2 months, and with chemotherapy, 6,7 months . The reported HR was 0,40 and p<0,0001. The result was equally strong in the RAS G12 population: OS was 13,2 vs 6,6 months, HR 0,40.

PFS also improved significantly. In the ITT population, median PFS was, with daraxonrasib, 7,2 months, and with chemotherapy, 3,6 months . The objective response rate in the entire population was %31,6 vs %11,2; in the RAS G12 population, it was %33,2 vs %11,8 as reported.

What did the study show about quality of life and pain?

In metastatic pancreatic cancer, not only survival but also pain and daily functioning are critically important. In RASolute 302, daraxonrasib significantly delayed the time to pain deterioration compared with chemotherapy. The HR for pain was 0,51, and the HR for global health status and quality of life was 0,60 as reported.

Safety

Daraxonrasib showed a generally manageable safety profile, and treatment discontinuation was less frequent than with chemotherapy. Nevertheless, it is not a treatment without side effects. The most frequent problems included rash, stomatitis/oral inflammation, nausea, diarrhea and mucosal inflammation. In the full results reported by Reuters, rash of any grade occurred at a rate of %86,3 as reported.

Enthusiasm and caution coexist

RASolute 302 became one of the most discussed studies at ASCO 2026. Some experts called the data a gamechanger, a grand slam and landscape-changing. The reason for this enthusiasm is clear: second-line median OS exceeding 13 months and a %60 reduction in the risk of death in pancreatic cancer represent an effect of a magnitude not previously seen at the randomized phase 3 level.

Critical comments also matter, however. Some academics pointed out that, before ASCO, the data were first announced in a press release, warning against medicine by press release. The NEJM publication has now largely addressed this concern, but the core debate remains valid: details of toxicity, emerging resistance, real-world feasibility, access, cost and applicability to the first-line setting must be followed carefully.

Why is this so important?

In pancreatic cancer, KRAS/RAS was considered undruggable for many years. Daraxonrasib represents a new approach that targets not only a particular KRAS variant but, more broadly, the active RAS(ON) state. RASolute 302 could therefore open a door not only for pancreatic cancer but also for RAS-dependent lung and colorectal cancers.

Conclusion

RASolute 302 showed that daraxonrasib substantially improved both overall survival and progression-free survival compared with standard chemotherapy in previously treated metastatic pancreatic cancer. In the ITT population, median OS was 13,2 months versus 6,7 months; PFS was 7,2 months versus 3,6 months; and the objective response rate was %31,6 versus %11,2.

These data make daraxonrasib a candidate for a new standard in second-line metastatic PDAC. More broadly, RASolute 302 is among the strongest pieces of evidence that RAS biology, once considered undruggable, can now be targeted clinically.